Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study.

ABSTRACT:

Background

Multiple studies and meta-analyses examined the role of traditional risk factors for cardiovascular events in statin treatment-naive patients. Nowadays, millions receive such therapy for the primary prevention of cardiovascular events (CVE).

Objective

CVEs still occur in patients on primary preventive statin therapy. Therefore, further risk stratification within these patients is urgently needed.

Methods

Using the unique linkage between biomedical data and prescription data from the PharmLines Initiative, we assessed the role of several risk factors used in cardiovascular risk models, using a time-dependent Cox PH model, in the occurrence of drug treatment of CVEs after initiation of statin therapy.

Results

Among 602 statin therapy starters, 11% rece

SUBMITTER: Steenhuis D 

PROVIDER: S-EPMC9155967 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature